AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.5 Million USD | -2.06% |
| 2022 | 5.61 Million USD | -10.35% |
| 2021 | 6.26 Million USD | 7.06% |
| 2020 | 5.85 Million USD | 4.66% |
| 2019 | 5.59 Million USD | 37.67% |
| 2018 | 4.06 Million USD | -6.48% |
| 2017 | 4.34 Million USD | 310.11% |
| 2016 | 1.05 Million USD | -19.51% |
| 2015 | 1.31 Million USD | 238.37% |
| 2014 | 388.87 Thousand USD | 679.72% |
| 2013 | 49.87 Thousand USD | 61.55% |
| 2012 | 30.87 Thousand USD | 233.43% |
| 2011 | -23.13 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 6.4 Million USD | 2.05% |
| 2024 Q1 | 6.27 Million USD | 14.03% |
| 2023 FY | 5.5 Million USD | -2.06% |
| 2023 Q2 | 5.62 Million USD | 6.24% |
| 2023 Q4 | 5.5 Million USD | -4.96% |
| 2023 Q3 | 5.78 Million USD | 2.97% |
| 2023 Q1 | 5.29 Million USD | -5.79% |
| 2022 Q3 | 5.44 Million USD | -1.42% |
| 2022 FY | 5.61 Million USD | -10.35% |
| 2022 Q4 | 5.61 Million USD | 3.12% |
| 2022 Q1 | 5.14 Million USD | -17.9% |
| 2022 Q2 | 5.52 Million USD | 7.41% |
| 2021 Q3 | 5.92 Million USD | 1.77% |
| 2021 Q4 | 6.26 Million USD | 5.78% |
| 2021 Q1 | 5.92 Million USD | 1.31% |
| 2021 Q2 | 5.82 Million USD | -1.83% |
| 2021 FY | 6.26 Million USD | 7.06% |
| 2020 FY | 5.85 Million USD | 4.66% |
| 2020 Q1 | 5.99 Million USD | 7.13% |
| 2020 Q2 | 4.72 Million USD | -21.17% |
| 2020 Q3 | 5.08 Million USD | 7.64% |
| 2020 Q4 | 5.85 Million USD | 15.13% |
| 2019 Q4 | 5.59 Million USD | 15.02% |
| 2019 FY | 5.59 Million USD | 37.67% |
| 2019 Q2 | 3.74 Million USD | 14.27% |
| 2019 Q1 | 3.27 Million USD | -19.28% |
| 2019 Q3 | 4.86 Million USD | 29.77% |
| 2018 Q3 | 4 Million USD | -21.21% |
| 2018 FY | 4.06 Million USD | -6.48% |
| 2018 Q4 | 4.06 Million USD | 1.53% |
| 2018 Q2 | 5.07 Million USD | -9.72% |
| 2018 Q1 | 5.62 Million USD | 29.49% |
| 2017 FY | 4.34 Million USD | 310.11% |
| 2017 Q2 | 1.78 Million USD | 50.11% |
| 2017 Q3 | 3.05 Million USD | 71.34% |
| 2017 Q4 | 4.34 Million USD | 41.97% |
| 2017 Q1 | 1.18 Million USD | 12.31% |
| 2016 Q4 | 1.05 Million USD | 100.8% |
| 2016 Q2 | 1.36 Million USD | 6.72% |
| 2016 Q1 | 1.27 Million USD | -2.8% |
| 2016 FY | 1.05 Million USD | -19.51% |
| 2016 Q3 | 527.47 Thousand USD | -61.36% |
| 2015 Q3 | 1.4 Million USD | -0.83% |
| 2015 Q4 | 1.31 Million USD | -6.46% |
| 2015 Q2 | 1.41 Million USD | 65.95% |
| 2015 Q1 | 854.74 Thousand USD | 119.8% |
| 2015 FY | 1.31 Million USD | 238.37% |
| 2014 Q1 | 49.87 Thousand USD | 0.0% |
| 2014 Q4 | 388.87 Thousand USD | 288.13% |
| 2014 Q3 | 100.19 Thousand USD | 121.85% |
| 2014 Q2 | 45.16 Thousand USD | -9.45% |
| 2014 FY | 388.87 Thousand USD | 679.72% |
| 2013 FY | 49.87 Thousand USD | 61.55% |
| 2013 Q4 | 49.87 Thousand USD | 2.27% |
| 2013 Q3 | 48.76 Thousand USD | -2.19% |
| 2013 Q1 | 35.57 Thousand USD | 15.22% |
| 2013 Q2 | 49.85 Thousand USD | 40.15% |
| 2012 Q4 | 30.87 Thousand USD | 511.24% |
| 2012 Q3 | -7507.00 USD | -367.14% |
| 2012 FY | 30.87 Thousand USD | 233.43% |
| 2012 Q1 | -39.13 Thousand USD | -69.15% |
| 2012 Q2 | -1607.00 USD | 95.89% |
| 2011 Q4 | -23.13 Thousand USD | -76.79% |
| 2011 Q3 | -13.08 Thousand USD | 0.0% |
| 2011 FY | -23.13 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 420092.061% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 2.593% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 87.143% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2304.109% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1703.9% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 187.269% |
| Qrons Inc. | 351.42 Thousand USD | -1465.587% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -784.032% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 87.333% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 27059.506% |
| Skye Bioscience, Inc. | -5.72 Million USD | 196.164% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 65.096% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -33.605% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1269.145% |
| SQZ Biotechnologies Company | -36.23 Million USD | 115.183% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -145.376% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -493.397% |
| Mesoblast Limited | 55.85 Million USD | 90.15% |
| Marizyme, Inc. | 18.56 Million USD | 70.371% |
| Genus plc | 190.6 Million USD | 97.113% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -146.078% |
| Pharming Group N.V. | 109.8 Million USD | 94.989% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -539.576% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -353.246% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -709.102% |
| ContraFect Corporation | -6.02 Million USD | 191.303% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3986.406% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -376.178% |
| IMV Inc. | 7.67 Million USD | 28.272% |
| MultiCell Technologies, Inc. | 90.04 USD | -6110401.999% |
| ONE Bio Corp. | 9.04 Million USD | 39.139% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 849.6% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 57.501% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -302.194% |
| Q BioMed Inc. | 4.06 Million USD | -35.514% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 81.993% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -445.977% |
| Biomind Labs Inc. | 711.4 Thousand USD | -673.388% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 90.913% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -175.178% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 57.039% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1429.537% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3835.435% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -27593.643% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -149.861% |
| GB Sciences, Inc. | 1.74 Million USD | -214.877% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 3093.61% |
| HST Global, Inc. | 96.79 Thousand USD | -5584.188% |
| CSL Limited | 10.52 Billion USD | 99.948% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2568.013% |
| Halberd Corporation | 144.72 Thousand USD | -3701.726% |
| Enzolytics Inc. | 981.65 Thousand USD | -460.471% |
| Agentix Corp. | 37.63 Thousand USD | -14520.648% |
| Resverlogix Corp. | 6.45 Million USD | 14.713% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 917.41% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.271% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 111.703% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 22.19% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -103.126% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 162.239% |
| AVAX Technologies, Inc. | -5.9 Million USD | 193.202% |
| Zenith Capital Corp. | 10.06 Thousand USD | -54569.078% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.518% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2645.019% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -130.587% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -3244.435% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 30135.462% |
| Kadimastem Ltd | -253.1 Thousand USD | 2273.786% |
| Helix BioMedix, Inc. | -2.57 Million USD | 314.079% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 72.865% |
| BioStem Technologies, Inc. | 4.47 Million USD | -23.03% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2633.807% |
| LadRx Corporation | -2.03 Million USD | 370.168% |
| Cell Source, Inc. | 9.23 Million USD | 40.404% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -766.213% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -766.213% |
| NovAccess Global Inc. | 2.17 Million USD | -152.558% |
| Affymax, Inc. | -5.59 Million USD | 198.301% |
| Itoco Inc. | 228.3 Thousand USD | -2309.889% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3945.839% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -10.992% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1036.211% |
| CytoDyn Inc. | 20.26 Million USD | 72.846% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 850470.325% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 59462.259% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 28.602% |
| SYBLEU INC | 473.71 Thousand USD | -1061.438% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -23.443% |
| International Stem Cell Corporation | 2.59 Million USD | -112.428% |
| Bioxytran, Inc. | 1.89 Million USD | -189.739% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -8715.305% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -152.276% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -60.218% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 35.673% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -612.121% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 540.152% |
| Neutra Corp. | 52.18 Thousand USD | -10442.656% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 321.048% |
| PureTech Health plc | -167.19 Million USD | 103.291% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2346.515% |
| IXICO plc | -4.44 Million USD | 223.789% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 58.379% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 89.969% |
| CSL Limited | 10.52 Billion USD | 99.948% |
| Cellectis S.A. | -43.81 Million USD | 112.556% |